William Ho

William Ho

Company: IN8Bio

Job title: CEO


Donor Derived Gamma-Delta T Cells; Path Towards Sold Tumor Therapies 9:30 am

Reviewing gamma-delta T cells; nonrestrictive lymphocytes that are thought to be attractive for allogeneic therapies Outlining our INB-100 phase I program, which is the first to have delivered a large bolus of ex-vivo expanded and mismatched gamma-delta T cells into lymphodepleted leukemia patients Providing safety data to advance our donor derived INB-400 program into the…Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.